Last reviewed · How we verify

NCT06870539

Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment

Completed Last updated 4 December 2025
What this trial tests

trial testing Non-Interventional Study in Cancer-related Cognitive Dysfunction in 49 participants. Completed in 31 July 2025.

Timeline
7 March 2025
Primary endpoint
31 July 2025
31 July 2025

Quick facts

Lead sponsorMayo Clinic
StatusCompleted
Study typeOBSERVATIONAL
Enrollment49
Start date7 March 2025
Primary completion31 July 2025
Estimated completion31 July 2025
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

18 and older, female only, with Cancer-related Cognitive Dysfunction or Cytomegaloviral Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the feasibility and accuracy of using saliva to remotely monitor cytomegalovirus (CMV) infection in individuals receiving treatment for ovarian cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Non-Interventional Study

Trials testing the same drug.

Other recruiting trials for Cancer-related Cognitive Dysfunction

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06870539.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing